Latest papers

Liver-associated macrophage precursor cells proliferate under impairment of regular hemopoiesis.

Preparation and release kinetics of hydrochlorothiazide from butyl half-ester of PVM/MA microcapsules.

Enhancement of lung colony formation by admixing irradiated with viable tumor cells: dependence on host status.

Expression of a 120,000 dalton protein during tumoricidal activation in murine peritoneal macrophages.

Increased therapeutic efficacy and reduced toxicity of doxorubicin linked to pyran copolymer via the side chain of the drug.

Augmentation of natural cell activity in tumor-bearing and normal mice by MVE-2.

Immune response by biological response modifiers.

The pulmonary antibody-forming cell response in the guinea pig after intratracheal immunization.

I-Ad antigen expression of pyran copolymer-induced peritoneal cells in tumor vaccine-primed mice and its association with the host antitumor response.

Phase II trial of MVE-II in metastatic malignant melanoma.

Inability of anti-asialo-GM1 and 2-chloroadenosine to abrogate maleic anhydride-divinyl ether-induced resistance against experimental murine lung carcinoma metastases.

Adjuvant chemoimmunotherapy of cancer: influence of tumor burden and role of functional immune effector cells in mice.

Effects of biological response modifiers on effector cells with cytotoxic activity against tumors.

In vivo induction of terminal differentiation of malignant myelopoietic progenitor cells by CSF-inducing biological response modifiers.

Preclinical approaches to the development of effective immunotherapeutic protocols for the treatment of metastasis.

Effects of hydroxyethylstarch (Hespan), a plasma expander, on the functional activity of the reticuloendothelial system. Comparison with human serum albumin and pyran copolymer.

Phase I study of MVE-2 evaluating toxicity and biologic response modification capability.

Clinical pharmacology of the biological response modifier maleic anhydride divinyl ether copolymer (MVE-2).

Antimicrobial activity of various immunomodulators: independence from normal levels of circulating monocytes and natural killer cells.

Augmentation of NK activity and/or macrophage-mediated cytotoxicity in the liver by biological response modifiers including human recombinant interleukin 2.